Opinions
James Hodgins
Inmed Pharmaceuticals
IN-T
RISKY
May 15, 2018
$1.010
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
Advertising
This is another company in the cannabis space. This is not a cannabis producer, it is a company that adds value in that space. They are mapping cannabinoids, looking for different formulations to treat different diseases.It is highly speculative, but he thinks there is opportunity for this type of company. He likes the management. In a growth market, as the US opens up, this could do very well. He owns stocks like this in a basket. He is not betting on any one of them; instead he is expecting the overall basket to do well.